Product
Supplier
Encyclopedia
Inquiry
Home > Chemicals Market Price & Insight > Ofloxacin Market Price & Analysis > Featured News - Ofloxacin > Fuxiang Pharmaceutical Will Achieve Operating Income of 1.493 Billion Yuan in 2020, and the Main Business Has Not Changed
— Share —

Fuxiang Pharmaceutical Will Achieve Operating Income of 1.493 Billion Yuan in 2020, and the Main Business Has Not Changed

healthoo 2021-04-25
During the reporting period, the company’s main business remained unchanged, focusing on the R&D, production and sales of high-end antibiotic APIs and their intermediates.

Please sign in to view all content or subscribe.

Comment
Comment

Trade Alert

Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.